In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...

The bladder cancer market is poised for transformative growth between 2025 and 2035, driven by rising global incidence rates, ...

Cohort B is evaluating efti in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

The deal structure is similar to a 2022 agreement ... A Phase 3 study is evaluating Padcev in combination with the Merck immunotherapy Keytruda as a treatment for muscle-invasive bladder cancer.

So when you look at the nature of that, particularly for the stop loss books, its drugs like Keytruda or Ocrevus ... undertake significant work to structure their benefits in a deliberate way ...

Only a few days prior, Sanofi also stated that it would simplify its R&D structure, but noted only ... Johnson & Johnson (Stelara), and Merck (Keytruda), among others. This need for capital ...

ALPENA — Home is more than a physical structure — it’s a place where ... “Dr. Hitzelberger said the medication Keytruda had to be tried as it was my best shot. My cancer was advanced ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...